| Ytd | -2.10% | |
| 1y | 189.17% |
| Open | 76.50 | Prev Close | 77.29 | Low | 75.49 | High | 77.01 | Mkt Cap | 599.89M |
| Vol | 35.73K | Avg Vol | 313.87K | EPS | -2.44 | P/E | -31.68 | Forward P/E | N/A |
| Beta | -5.34 | Short Ratio | 0.70 | Inst. Own | 44.28% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 73.23 | 200-d Avg | 75.09 | 1yr Est | 4.87 |
DRUG News
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric
https://www.hhs.gov/press-room/fda-accelerates-action-treatments-serious-mental-illness-following-ex
https://www.cbsnews.com/news/psychedelic-drug-ibogaine-ptsd-trump-to-sign-executive-order/
Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report) has been given a consensus recommenda
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or
Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report) has been assigned an average rating o
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG)
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG)
Bright Minds Biosciences remains a "Strong Buy" after positive phase 2 data for BMB-101 in drug-resi
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG)
Bright Minds Biosciences Inc. (NASDAQ: DRUG) stock is trading higher on Tuesday after the company sh
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG)
Shares of Bright Minds Biosciences Inc (NASDAQ: DRUG, CSE:DRUG) jumped almost 25% after the company
– Conference Call and Live Webcast at 8AM ET – NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Mi
Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report)'s share price rose 4.2% during tradin
Shares of Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report) have received an average ra
For three decades, central nervous system (CNS) drug development was a tough space for investors, sc
Bright Minds Biosciences Inc. (DRUG) made it through our "Recent Price Strength" screen and could be
NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or
The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in Br
Days after starting a new investigational program, it announced four appointments to its scientific
On Thursday, 369 companies hit new 52-week lows.
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
Tuesday's session saw 729 companies set new 52-week lows.